Page 250 - Drug Class Review
P. 250
Page 155 of 205
Drug Effectiveness Review Project
rivastigmine 74.9 64 20.7 20.8 50% Primary Outcome Measures: ADAS-Cog (blinded rater); MMSE (un-blinded clinician) Secondary Outcome Measures: Satisfaction/ease of use as measured by questionnaire developed by Physicians reported better mean total satisfaction/ease of use with DON than with RIV at 12 Caregivers reported better mean total satisfaction/ease of use with DON than with RIV at 12 No statistically significant differences between DON and RIV as measured by ADAS-Cog
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes
Health Outcome Measures: weeks (P < 0.05)
donepezil 74.0 54 21.5 20.4 48% Pfizer and Eisai (clinician and caregiver satisfaction/ease of use) Timing of assessments: Baseline and weeks 4 and 12 weeks (P < 0.0001) Intermediate Outcome Measures: (blinded rater) and MMSE (un-blinded clinician)*
• • •
Final Report Update 1 Authors: Wilkinson et al. Year: 2002 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Other germane population qualities: Mean baseline MMSE score • Mean baseline ADAS-Cog • Taking ≥ 1 concomitant med • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
